[Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin].
Skin abnormalities are the most common manifestations in patients with systemic sclerosis but many other organs can be involved. We report here the case of a 61 year-old-man in whom small bowel involvement was the initial presentation of limited systemic sclerosis. The clinical features consisted of recurrent small bowel obstruction without any organic lesion. The patient responded well to erythromycin (125 mg thrice a day before meals) and octreotide (50 microg subcutaneously at bedtime) with complete symptom relief. This permitted recovery of nutritional autonomy for two years. This observation shows that, in patients with intestinal pseudo-obstruction, systemic sclerosis should be considered. The long-term administration of octreotide and erythromycin can be effective in treating small bowel dysmotility in such patients.
Lecomte
T
T
Service d'Hépatologie et de Gastroentérologie, Hôpital Henri-Mondor, Créteil.
Cavicchi
M
M
Delchier
J C
JC
D000974:Antibodies, Antinuclear / Q000097:blood; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007418:Intestinal Pseudo-Obstruction / Q000188:drug therapy* / Q000209:etiology*; D007421:Intestine, Small; D008134:Long-Term Care / Q000379:methods; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D012008:Recurrence; D012595:Scleroderma, Systemic / Q000097:blood / Q000150:complications* / Q000175:diagnosis* / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
D000974:Antibodies, Antinuclear; D005765:Gastrointestinal Agents; D004917:Erythromycin; D015282:Octreotide